Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 33Other hematologic neoplasm 16Plasma cell 8Myeloid 5Dermatologic 3Thoracic 1Sarcoma 1Other solid neoplasm 1Other neoplasm 1Gynecologic 1Genitourinary 1

Conditions

Ovarian Neoplasms 1006Uterine Cervical Neoplasms 420Endometrial Neoplasms 350Carcinoma, Non-Small-Cell Lung 292Breast Neoplasms 292Neoplasms 238Colorectal Neoplasms 233Fallopian Tube Neoplasms 211Stomach Neoplasms 192Pancreatic Neoplasms 184Melanoma 157Prostatic Neoplasms 152Triple Negative Breast Neoplasms 148Carcinoma, Ovarian Epithelial 147Lung Neoplasms 136Neoplasm Metastasis 133Squamous Cell Carcinoma of Head and Neck 131Carcinoma, Renal Cell 130Head and Neck Neoplasms 122Esophageal Neoplasms 121Urinary Bladder Neoplasms 112Small Cell Lung Carcinoma 90Sarcoma 80Carcinoma, Hepatocellular 76Recurrence 70Carcinoma, Transitional Cell 70Uterine Cervical Dysplasia 66Papillomavirus Infections 66Colonic Neoplasms 59Cholangiocarcinoma 59

Interventions

enzalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Immune System Diseases × Gynecologic × Clear all
NCT04104776 2025-05-15

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Novartis

Phase 1/2 Recruiting
275 enrolled
GenitourinaryGynecologicLymphoidOther solid neoplasmThoracic

Mesothelioma, Malignant, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Endometrial Neoplasms, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡